At first glance, it’s hard to imagine anything as obscure as a policy by a private contracting firm that runs the Medicare program in the Carolinas, Virginia and West Virginia.
As the debate around Galleri, the multi-cancer detection test developed by GRAIL Inc., rages on, fueled most recently by the full-steam-ahead support it has received from regulatory and legislative bodies, NCI Director Anthony Letai has turned his attention to the available data.
